Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-27T21:43:23.621Z Has data issue: false hasContentIssue false
  • English
  • Français

Rationale for using new lipid emulsions in parenteral nutrition and a review of the trials performed in adults – Corrigendum

Published online by Cambridge University Press:  20 January 2011

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Corrigendum
Information
Proceedings of the Nutrition Society , Volume 70 , Issue 2 , May 2011 , pp. 281
Copyright
Copyright © The Author 2011

In the subsection ‘Fish oil in parenteral nutrition’ on page 255 (column 2, lines 28–29) incorrect information about the EPA plus DHA content of Lipoplus is given.(Reference Calder1)

The information provided (0·6 g per 100 ml) was calculated based upon the EPA and DHA contents of a standard fish oil. However Lipoplus contains more concentrated marine n-3 fatty acids as reported by Driscoll et al. (Reference Driscoll, Ling and Bistrian2) Therefore the statement should read:

Each 100 ml of Lipoplus will typically contain about 1·2 g EPA+DHA.

References

1.Calder, PC (2009) Rationale for using new lipid emulsions in parenteral nutrition and a review of the trials performed in adults. Proc Nutr Soc 68, 252–260.CrossRefGoogle Scholar
2.Driscoll, DF, Ling, PR, Bistrian, BR (2009) Pharmacopeial compliance of fish oil-containing parenteral lipid emulsion mixtures: Globule size distribution (GSD) and fatty acid analyses. Int J Pharmaceut 379, 125–130.CrossRefGoogle ScholarPubMed